BEIJING, Dec. 8, 2024 /PRNewswire/ — “Hello everyone, this is Laolu…” Olivier, a Frenchman who has lived in China for 30 years, speaks fluent Chinese and is a natural in front of the camera. When asked why he came to Yuhang, Olivier laughed and said, “There are too many things worth exploring here, such as Liangzhu culture. Of course, good tea is also one thing.”
jwplayer(‘myplayer1’).setup(file: ‘https://mma.prnasia.com/media2/2575871/Yuhang_Journey___Follow_Olivier_to_Explore_Ancient_Liangzhu_and_Savor_Jingshan_Tea.mp4’, image: ‘https://mma.prnasia.com/media2/2575871/Yuhang_Journey___Follow_Olivier_to_Explore_Ancient_Liangzhu_and_Savor_Jingshan_Tea.mp4?p=medium’, autostart:’false’, stretching : ‘uniform’, width: ‘512’, height: ‘288’);
In the series “Report on China: Focus on Yuhang,” Olivier was specially invited to be the Yuhang broadcaster. Through his perspective, we’ll delve into the rich and vibrant history and culture of Yuhang, explore Liangzhu culture, savor Jingshan tea, and experience the enduring charm of Chinese civilization.
Liangzhu culture is one of the most significant ancient cultures in Zhejiang. As the capital of the ancient Zhejiang Kingdom, Liangzhu’s urban planning, production methods, and exquisite jade artifacts make it a dazzling gem of Neolithic culture. Meanwhile, Yuhang’s Jingshan Tea Garden holds a prominent place in the world of tea culture.
In this program, we’ll first visit the Ruins of Liangzhu City to explore this historical treasure and observe its intricate cultural relics up close. Then, we’ll head to Jingshan Tea Garden, retracing the footsteps of the “Father of Tea,” Lu Yu, alongside Olivier, and immerse ourselves in the splendid traditions of Jingshan tea culture.
ข่าวที่เกี่ยวข้อง
- World Young Scientist Summit 2026 Opens in Wenzhou, Zhejiang
- The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
- Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
- 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
